1 |
Immune-active CHB |
Antiviral therapy |
No treatment |
Cirrhosis, decompensation, HCC, death, loss of HBsAg |
2 |
Immune-tolerant CHB, adults |
Antiviral therapy |
No treatment |
Cirrhosis, decompensation, HCC, death, loss of HBsAg |
3 |
HBeAg-positive immune-active chronic hepatitis, with HBeAg seroconversion on therapy |
Continued antiviral therapy |
Stopping antiviral therapy |
Cirrhosis, HCC, reactivation, seroreversion, decompensation, loss of HBsAg |
4 |
HBeAg-negative immune-active chronic hepatitis, with viral suppression on antiviral therapy |
Continued antiviral therapy |
Stopping antiviral therapy |
Reactivation, decompensation, loss of HBsAg |
5 |
CHB on treatment with oral therapy |
Tenofovir |
Entecavir |
Renal function, hypophosphatemia, bone health |
6 |
CHB on treatment with oral therapy with persistent viremia |
Continue therapy |
Change or switch therapy |
HBV resistance, clinical flare, decompensation, loss of HBeAg |
7 |
CHB with cirrhosis, with HBV DNA <2,000 IU/mL |
Antiviral therapy |
No treatment |
Decompensation, HCC, death |
8 |
Pregnant women with CHB |
Antiviral therapy in third trimester |
No treatment |
CHB in the infant, maternal safety, fetal/infant safety |
9 |
HBeAg-positive CHB, children/adolescents |
Antiviral therapy |
No treatment |
Cirrhosis, decompensation, HCC, death, HBeAg seroconversion, loss of HBsAg |